-$0.25 EPS Expected for Nantkwest Inc (NK) This Quarter
Brokerages expect Nantkwest Inc (NASDAQ:NK) to report earnings of ($0.25) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Nantkwest’s earnings. The company is scheduled to report its next earnings report on Wednesday, August 14th.
On average, analysts expect that Nantkwest will report full-year earnings of ($0.82) per share for the current financial year. For the next fiscal year, analysts expect that the company will report earnings of ($0.38) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow Nantkwest.
Separately, Zacks Investment Research lowered shares of Nantkwest from a “buy” rating to a “hold” rating in a research report on Tuesday, January 15th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. Nantkwest currently has a consensus rating of “Hold” and an average target price of $2.33.
A number of hedge funds have recently modified their holdings of NK. JPMorgan Chase & Co. boosted its holdings in shares of Nantkwest by 132.8% in the third quarter. JPMorgan Chase & Co. now owns 111,641 shares of the biotechnology company’s stock valued at $413,000 after acquiring an additional 63,689 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Nantkwest by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 241,815 shares of the biotechnology company’s stock valued at $895,000 after acquiring an additional 25,543 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Nantkwest by 34.6% in the third quarter. Renaissance Technologies LLC now owns 700,567 shares of the biotechnology company’s stock valued at $2,592,000 after acquiring an additional 180,167 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Nantkwest by 33.4% in the fourth quarter. Rhumbline Advisers now owns 38,242 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 9,570 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Nantkwest in the fourth quarter valued at about $49,000. 8.52% of the stock is owned by hedge funds and other institutional investors.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Featured Story: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.